These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 19416014)

  • 1. Human Lyme disease vaccines: past and future concerns.
    Nardelli DT; Munson EL; Callister SM; Schell RF
    Future Microbiol; 2009 May; 4(4):457-69. PubMed ID: 19416014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccines against Lyme disease: What happened and what lessons can we learn?
    Poland GA
    Clin Infect Dis; 2011 Feb; 52 Suppl 3():s253-8. PubMed ID: 21217172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correcting a public health fiasco: The need for a new vaccine against Lyme disease.
    Plotkin SA
    Clin Infect Dis; 2011 Feb; 52 Suppl 3():s271-5. PubMed ID: 21217175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Lyme disease vaccine--a public health perspective.
    Shen AK; Mead PS; Beard CB
    Clin Infect Dis; 2011 Feb; 52 Suppl 3():s247-52. PubMed ID: 21217171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of the Lyme disease vaccine.
    Hsia EC; Chung JB; Schwartz JS; Albert DA
    Arthritis Rheum; 2002 Jun; 46(6):1651-60. PubMed ID: 12115198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progress and controversy surrounding vaccines against Lyme disease.
    Hanson MS; Edelman R
    Expert Rev Vaccines; 2003 Oct; 2(5):683-703. PubMed ID: 14711329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Lyme vaccine: a cautionary tale.
    Nigrovic LE; Thompson KM
    Epidemiol Infect; 2007 Jan; 135(1):1-8. PubMed ID: 16893489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preview: Lyme disease vaccines.
    Donnelly EF
    Med Health R I; 1998 Nov; 81(11):373-5. PubMed ID: 15580796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reactogenicity and immunogenicity of a Lyme disease vaccine in children 2-5 years old.
    Beran J; De Clercq N; Dieussaert I; Van Hoecke C
    Clin Infect Dis; 2000 Dec; 31(6):1504-7. PubMed ID: 11096024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lyme vaccine demonized by advocacy groups.
    McSweegan E
    Nature; 2006 Mar; 440(7082):278. PubMed ID: 16541048
    [No Abstract]   [Full Text] [Related]  

  • 11. Vaccine development: how scientific collaboration and communication help prevent the spread of disease: an interview with Erol Fikrig, MD.
    Fikrig E; Turchick A; Czochor J
    Yale J Biol Med; 2014 Dec; 87(4):519-25. PubMed ID: 25506284
    [No Abstract]   [Full Text] [Related]  

  • 12. Asymptomatic infection with Borrelia burgdorferi.
    Steere AC; Sikand VK; Schoen RT; Nowakowski J
    Clin Infect Dis; 2003 Aug; 37(4):528-32. PubMed ID: 12905137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A systematic review and meta-analysis for the adverse effects, immunogenicity and efficacy of Lyme disease vaccines: Guiding novel vaccine development.
    Badawi A; Shering M; Rahman S; Lindsay LR
    Can J Public Health; 2017 Apr; 108(1):e62-e70. PubMed ID: 28425901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Should speculations about immune-mediated adverse effects of Lyme disease vaccine deter us from giving it?
    Sigal L
    Cleve Clin J Med; 2000 Dec; 67(12):873-4. PubMed ID: 11127980
    [No Abstract]   [Full Text] [Related]  

  • 15. Antigen Engineering Approaches for Lyme Disease Vaccines.
    Federizon J; Lin YP; Lovell JF
    Bioconjug Chem; 2019 May; 30(5):1259-1272. PubMed ID: 30987418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Lyme vaccine: a cautionary tale.
    McSweegan E
    Epidemiol Infect; 2007 Jan; 135(1):9-10. PubMed ID: 17064458
    [No Abstract]   [Full Text] [Related]  

  • 17. The rise and fall of the lyme disease vaccines: a cautionary tale for risk interventions in American medicine and public health.
    Aronowitz RA
    Milbank Q; 2012 Jun; 90(2):250-77. PubMed ID: 22709388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity profile of a recombinant outer-surface protein A Lyme disease vaccine: clinical trial of a 3-dose schedule at 0, 1, and 2 months.
    Schoen RT; Sikand VK; Caldwell MC; Van Hoecke C; Gillet M; Buscarino C; Parenti DL
    Clin Ther; 2000 Mar; 22(3):315-25. PubMed ID: 10963286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inner Workings: Lyme disease vaccines face familiar challenges, both societal and scientific.
    Shaffer L
    Proc Natl Acad Sci U S A; 2019 Sep; 116(39):19214-19217. PubMed ID: 31554734
    [No Abstract]   [Full Text] [Related]  

  • 20. The prevention of Lyme disease with vaccine.
    Poland GA; Jacobson RM
    Vaccine; 2001 Mar; 19(17-19):2303-8. PubMed ID: 11257352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.